CReactive Protein Testing Market

C-Reactive Protein Testing Market Size

The global C-reactive protein testing market was valued at USD 3.3 billion in 2024 and is expected to reach USD 4.8 billion in 2034 with a CAGR of 4.1% from 2025 to 2034. The growth market is being driven by the rising prevalence of chronic disorders, along with an increased demand for CRP testing for the effective diagnosis and management of these conditions.

Diseases such as rheumatoid arthritis, diabetes, and cardiovascular conditions require continuous attention, which can be made easier through CRP testing. Monitoring and the early detection of chronic conditions fuel the need for CRP testing. The World Health Organization reported that in 2023, nearly 71 percent of deaths worldwide were due to chronic illnesses, which further highlights the demand for precise and reliable CRP tests. There is an increasing geriatric population that requires constant monitoring, which is why there is a rising need for these tests.

Testing for C-reactive protein (CRP) measures the concentration of C-reactive protein produced by the liver in response to inflammation. Triggers like infections, autoimmune diseases, and atherosclerosis can invoke either acute or chronic inflammation, which can be indicated by elevated levels of CRP. The testing aids in identifying and tracking the progress of inflammatory diseases, gauging the severity of infections, and estimating the risk of heart ailments.

C-Reactive Protein Testing Market Trends

Advances in testing technology are improving the speed, ease, reliability, and accuracy of CRP testing, making it easier to monitor and diagnose inflammatory diseases. These changes are driving growth in the market.

• Recent advancements in point-of-care testing (POCT) allow immediate onsite CRP testing with results available instantly. Furthermore, new innovations allow for the development of highly sensitive CRP assays that can detect trace amounts of CRP. These innovations are important for the assessment of cardiovascular disease risk. The latest hs-CRP tests provide better sensitivity and specificity, thus making them important for early diagnosis and preventive care.
  
• Moreover, newer CRP testing methods are more often integrated with digital health systems and EHRs. Such integration enables effective data management, real-time tracking, and improvement of patient care, as well as more informed clinical decisions. These advancements in CRP testing technology improve its efficiency and ease of use, which contributes to global market expansion.
  

Trump Administration Tariffs

• The U.S.-China trade tensions will likely lead to future tariff policies, which may increase the price of imported parts and devices, in turn raising the cost of C-reactive protein testing products, especially in the U.S. market.
  
• In order to sidestep some of these costs, manufacturers may shift production or assembly work to countries that do not impose tariffs. These moves might influence lead time along with overall product availability.
  
• Some of these costs could be transferred to end users, making it more difficult for hospitals and clinics to adhere to budgets, particularly in sensitive areas.
  
• In contrast, developed countries could stimulate local innovation and the manufacturing of mapping systems and components due to the lack of other options.
  

C-Reactive Protein Testing Market Analysis

In 2021, the global market was valued at USD 3 billion. The following year, it saw a slight increase to USD 3.1 billion, and by 2023, the market further climbed to USD 3.2 billion. Based on product, the market is classified into instruments and kits and reagents. The kits and reagents segment dominated the market with a revenue of 2 billion in 2024. Also,

• The offered reagents and kits have a wide range of applicability as they can be integrated with various instruments and platforms, which makes them appropriate for multiple types of CRP assays, such as Chemiluminescence Immunoassay  (CLIA), ELISA, and Immunoturbidimetric Assays. This versatility allows their use in different clinical environments.
  
• Moreover, a considerable number of CRP testing kits allow ease of use and fast generation of results, which is essential in clinical settings where action must be taken immediately. The usefulness and efficiency of these kits are the reasons why they are often favored over complex and time-consuming procedures.
  

Based on assay type, the C-reactive protein testing market is classified into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and other assay types. The immunoturbidimetric assay procedures segment held a dominant market share in 2024 and was valued at over USD 1.2 billion.

• Relative to other assays, such as chemiluminescence immunoassay (CLIA) or even enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assays stand out as less expensive. This cost efficiency increases their scope of applicability, enabling small clinics or even some underfunded laboratories with limited financial resources to integrate them.
  
• Furthermore, these assays provide optimal results in processing time, as the results are received promptly—crucial in clinical practice where action needs to be taken right away. The rapid achievement of results enhances the speed of diagnosing and managing inflammatory conditions, which supports their broader use.
  

Based on detection range, the C-reactive protein testing market is classified into high-sensitivity CRP (Hs-CRP) and standard CRP. The standard CRP segment dominated the market in 2024 and is anticipated to reach USD 2.6 billion by the end of the forecast period.

• Relative to other assays, such as chemiluminescence immunoassay (CLIA) or enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assays stand out as less expensive. This cost efficiency increases their scope of applicability, enabling small clinics or even underfunded laboratories with limited financial resources to use them.
  
• Furthermore, these assays provide optimal processing time, as results are received promptly—which is crucial in clinical practice where immediate action is required. The rapid delivery of results enhances the speed of diagnosing and managing inflammatory conditions, supporting growth in this area.
  

Based on application, the C-reactive protein testing market is classified into cardiovascular diseases, infectious diseases, chronic inflammatory diseases, and other applications. The cardiovascular diseases segment held a dominant market share in 2024 and was valued at over USD 1.2 billion.

• The impact cardiovascular disease has on a diverse cohort of patients is considerably high and accounts for significant disease prevalence and mortality globally. The growing use of CRP testing, due to the increased need for assessing CVD risks during initial evaluation or ongoing surveillance, is well documented.
  
• In addition, CRP testing has been integrated into standard procedures related to cardiac care for patients with documented cardiovascular disease. Determining CRP levels helps measure the effectiveness of treatment and aids in the choice of therapy, thereby increasing its utility in this market.
  

Based on end use, the market is segmented into hospitals and clinics, diagnostic laboratories, and other end uses. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 2.4 billion by the end of the forecast period.

• Assessing CRP is routinely done in hospitals and clinics to assist with immediate clinical decisions. Quick processing of CRP tests helps healthcare practitioners in the timely evaluation and treatment of infections, inflammatory disorders, acute heart diseases, and other conditions that may require urgent attention.
  
• Moreover, clinics and hospitals cater to a multidisciplinary patient population, including those from internal medicine, cardiology, infectious diseases, and rheumatology. The multi-departmental application of CRP testing increases its usefulness and, therefore, its need among such facilities.
  

The U.S. C-reactive protein testing market accounted for USD 1.1 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 3.2% between 2025 to 2034.

• The focus on preventive care is increasing in the U.S., which contributes to the demand for CRP testing as a routine health check-up and screening measure. Moreover, healthcare policies supportive of early intervention and preventive strategies are strong factors fueling growth in the market.
  
• Painful health diseases have received more study, as well as something as basic as inflammatory diseases, which increases educational awareness of growing health issues. This encourages both patients and health providers to make use of CRP tests for inflammation disease management, monitoring, tracking, and better supervision of inflammatory diseases.
  

In the Europe C-reactive protein testing market, the UK is projected to grow remarkably in the coming years.

• Based on its guidance, the NHS—the UK’s health authority—routinely stores and tracks CRP levels, which are considered primary inflammatory markers, within the healthcare system. Chronic disease guidelines and recommendations by NICE are regularly used to manage and administer care effectively. These are documented for long-term reference and consistent use.
  
• In addition, there is greater demand for CRP testing due to the growing number of elderly people in the UK who suffer from chronic and inflammatory diseases. There is an increasing need for inflammation monitoring tools to support health assessments in line with the aging population.
  

In the Asia Pacific C-reactive protein testing market, Japan is anticipated to witness robust growth over the forecast period.

• Japan's strong technical focus, along with socialization, healthcare innovation, and research development, drives the growth of CRP testing. The broad and advanced clinical practices, CRP diagnostic technologies, and routine integrated testing support market expansion.
  
• Public authorities in Japan have long encouraged the use of CRP tests and other diagnostic measures as part of comprehensive chronic disease screening programs aimed at preventive healthcare for early diagnosis. These programs, which routinely include CRP tests for monitoring inflammatory activity and managing health conditions, support market growth.
  

C-Reactive Protein Testing Market Share

The market has a unique structure, where five major companies control about 55% of the market. These industry leaders include well-known names like Abbott, Agilent Technologies, Roche, and Merck. The development and launch of novel products and advanced solutions with improved functionality and cost-effectiveness are key market strategies for C-reactive protein testing product manufacturers and providers, driving competition and innovation in the industry. This emphasis on innovation aims to enable streamlined processing in a healthcare environment, positioning companies to gain market share and meet the growing demand for advanced C-reactive protein testing.

C-Reactive Protein Testing Market Companies

Prominent players operating in the C-reactive protein testing industry include:

• Abbott
• Agilent
• AIDIAN
• Boditech
• Creative Diagnostics
• CTK BIOTECH
• Danaher
• DxGen Corp
• Getein Biotech
• GOLDSITE
• HORIBA
• Labcorp
• Merck
• OptiBio
• RANDOX
• Roche
• SIEMENS Healthineers
  
• Abbott excels in delivering groundbreaking healthcare solutions across diagnostics, medical devices, nutrition, and pharmaceuticals, making it a versatile player in the industry. Abbott’s strategic focus on affordability, particularly in emerging markets. By investing heavily in research and development, Abbott continues to drive advancements in patient care while maintaining a strong commitment to improving lives worldwide.
  
• Siemens Healthineers is a global leader in medical technology, offering innovative solutions across diagnostic imaging, laboratory diagnostics, and digital health. Their strong focus on research and development drives advancements in healthcare, while their commitment to sustainability ensures a positive societal and environmental impact. By collaborating closely with healthcare providers, Siemens Healthineers addresses critical challenges, enhances efficiency, and ultimately improves patient outcomes.
  

C-Reactive Protein Testing Industry News:

• In January 2022, LumiraDx announced that its C-reactive protein (CRP) Test achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated microfluidic immunoassay test used for the quantitative determination of C-reactive protein, with results available within four minutes. This approval improved the company’s product offering and increased its reputation in the market.
  
• ?In September 2021, HORIBA UK Limited launched its new generation Microsemi CRP point-of-care hematology analyser. This launch increased the company’s competitiveness in the market.
  

The C-reactive protein testing market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Kits and reagents

Market, By Assay Type

• Chemiluminescence immunoassay (CLIA)
• Enzyme-linked immunosorbent assay (ELISA)
• Immunoturbidimetric assay
• Other assay types

Market, By Detection Range

• High-sensitivity CRP (hs-CRP)
• Standard CRP

Market, By Application

• Cardiovascular diseases
• Infectious diseases
• Chronic inflammatory diseases
• Other applications

Market, By End Use

• Hospitals and clinics
• Diagnostic laboratories
• Other end uses

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE